Antibacterial Properties of Four Novel Hit Compounds from a Methicillin-Resistant Staphylococcus aureus-Caenorhabditis elegans High-Throughput Screen by Tharmalingam, Nagendran et al.
University of Wollongong 
Research Online 
Illawarra Health and Medical Research Institute Faculty of Science, Medicine and Health 
1-1-2018 
Antibacterial Properties of Four Novel Hit Compounds from a Methicillin-











Massachusetts General Hospital 
See next page for additional authors 
Follow this and additional works at: https://ro.uow.edu.au/ihmri 
 Part of the Medicine and Health Sciences Commons 
Recommended Citation 
Tharmalingam, Nagendran; Rajmuthiah, Rajmohan; Kim, Wooseong; Fuchs, Beth; Jeyamani, Elamparithi; 
Kelso, Michael J.; and Mylonakis, Eleftherios, "Antibacterial Properties of Four Novel Hit Compounds from 
a Methicillin-Resistant Staphylococcus aureus-Caenorhabditis elegans High-Throughput Screen" (2018). 
Illawarra Health and Medical Research Institute. 1416. 
https://ro.uow.edu.au/ihmri/1416 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Antibacterial Properties of Four Novel Hit Compounds from a Methicillin-
Resistant Staphylococcus aureus-Caenorhabditis elegans High-Throughput 
Screen 
Abstract 
There is an urgent need for the discovery of effective new antimicrobial agents to combat the rise of 
bacterial drug resistance. High-throughput screening (HTS) in whole-animal infection models is a 
powerful tool for identifying compounds that show antibacterial activity and low host toxicity. In this 
report, we characterize the activities of four novel antistaphylococcal compounds identified from an HTS 
campaign conducted using Caenorhabditis elegans nematodes infected with methicillin-resistant 
Staphylococcus aureus (MRSA). The hit compounds included an Nhydroxy indole-1, a substituted 
melamine derivative-2, N-substituted indolic alkyl isothiocyanate-3, and pdifluoromethylsulfide analog-4 of 
the well-known protonophore carbonyl cyanide m-chlorophenyl hydrazone. Minimal inhibitory 
concentrations (MICs) of the four compounds ranged from 2 to 8 μg/ml against MRSA-MW2 and 
Enterococcus faecium and all were bacteriostatic. The compounds were mostly inactive against Gram-
negative pathogens, with only 1 and 4 showing slight activity (MIC= 32 μg/ml) against Acinetobacter 
baumanii. Compounds 2 and 3 (but not 1 or 4) were found to perturb MRSA membranes. In phagocytosis 
assays, compounds 1, 2, and 4 inhibited the growth of internalized MRSA in macrophages, whereas 
compound 3 showed a remarkable ability to clear intracellular MRSA at its MIC ( p < 0.001). None of the 
compounds showed hemolytic activity at concentrations below 64 μg/ml ( p = 0.0021). Compounds 1, 2, 
and 4 (but not 3) showed synergistic activity against MRSA with ciprofloxacin, while compound 3 
synergized with erythromycin, gentamicin, streptomycin, and vancomycin. In conclusion, we describe four 
new antistaphylococcal compounds that warrant further study as novel antibacterial agents against 
Gram-positive organisms. 
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Abstract 22 
There is an urgent need for the discovery of effective new antimicrobial agents to combat the rise 23 
of bacterial drug resistance. High-throughput screening (HTS) in whole-animal infection models 24 
is a powerful tool for identifying compounds that show antibacterial activity and low host toxicity. 25 
In this report, we characterize the activities of four novel anti-staphylococcal compounds identified 26 
from a HTS campaign conducted using Caenorhabditis elegans nematodes infected with 27 
methicillin-resistant Staphylococci aureus (MRSA). The hit compounds included: an N-hydroxy 28 
indole- 1, a substituted melamine derivative- 2, an N-substituted indolic alkyl isothiocyanate- 3, 29 
and  a p-difluoromethylsulfide analog- 4 of the well-known protonophore carbonyl cyanide m-30 
chlorophenyl hydrazone (CCCP). Minimal inhibitory concentrations (MICs) of the four 31 
compounds ranged from 2-8 µg/mL against MRSA-MW2 and Enterococcus faecium and all were 32 
bacteriostatic. The compounds were mostly inactive against Gram-negative pathogens, with only 33 
1 and 4 showing slight activity (MIC = 32 µg/mL) against Acinetobacter baumanii. Compounds 2 34 
and 3 (but not 1 or 4) were found to perturb MRSA membranes. In phagocytosis assays, 35 
compounds 1, 2 and 4 inhibited the growth of internalized MRSA in macrophages, whereas 36 
compound 3 showed a remarkable ability to clear intracellular MRSA at its MIC (p<0.001). None 37 
of the compounds showed hemolytic activity at concentrations below 64 µg/mL (p=0.0021). 38 
Compounds 1, 2 and 4 (but not 3) showed synergistic activity against MRSA with ciprofloxacin, 39 
while compound 3 synergized with erythromycin, gentamicin, streptomycin and vancomycin. In 40 
conclusion, we describe four new anti-staphylococcal compounds that warrant further study as 41 
novel antibacterial agents against Gram-positive organisms.  42 
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Introduction 43 
Antibiotic resistance is a major current and future threat to the global population, and new 44 
antibiotics are urgently needed to combat the inexorable rise of multi-drug resistant bacteria. 45 
Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen1 that can 46 
cause localized and systemic infections 2. Drug resistance in MRSA occurs primarily through the 47 
production of β-lactamases or altered penicillin binding proteins 3. According to the Center for 48 
Disease Control and Prevention (CDC), in the U.S. there are more than 11,000 deaths and 80,000 49 
severe cases of MRSA infection each year 4. Vancomycin has typically been the choice of 50 
antibiotic against serious multi-drug resistant Gram-positive bacterial infections but reports of 51 
vancomycin-resistant S. aureus are now common 5. Combination antimicrobial treatment is a 52 
promising strategy 6.  53 
Development of new antimicrobial agents has significantly declined in the past two 54 
decades due to challenging regulatory guidelines, perceptions around poor financial returns and 55 
difficulties in discovering the mechanism of action of new compounds 7. But, the whole animal 56 
Caenorhabditis elegans-based high throughput screening provides a powerful tool for identifying 57 
new antimicrobial agents, anti-virulence agents and immunomodulators. To identify novel 58 
antibacterial leads, we have employed C. elegans as a simple whole-animal host for studying 59 
infections of human pathogens 8. We recently completed a C. elegans high-throughput screen 60 
(HTS) to identify small molecules that are active against MRSA and show low host toxicity 9. This 61 
report details the broader antibacterial properties of four novel anti-staphylococcal hit compounds 62 
discovered during an MRSA-C. elegans high-throughput screening campaign. 63 
  64 
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Materials and Methods 65 
Bacterial and nematode strains. Bacteria were all from the Mylonakis laboratory collection 66 
(Table 1). S. aureus MW2 and Enterococcus faecium ATCC E007 were grown in tryptic soy broth 67 
(TSB) (BD Biosciences, Franklin Lakes, NJ, USA); Klebsiella pneumoniae ATCC 77326, 68 
Acinetobacter baumannii ATCC 17978, Pseudomonas aeruginosa PA14 and Enterobacter 69 
aerogenes EAE 2625 strains were grown in Luria-Bertani broth (LB) (BD Biosciences). All strains 70 
were grown at 37 °C. The C. elegans glp-4(bn2);sek-1(km4) double mutant strain was maintained 71 
at 15 °C on lawns of Escherichia coli HB101 on 10 cm plates 9. The glp-4(bn2) mutation renders 72 
the strain unable of producing progeny at 25 °C 10, and the sek-1(km4) mutation increases 73 
sensitivity to pathogens 11, reducing assay time. 74 
C. elegans-MRSA liquid infection assays. The C. elegans-MRSA infection assay has been 75 
described previously 9. In brief, C. elegans glp-4(bn2);sek-1(km4) worms were grown at 25 °C and 76 
harvested with M9 buffer. MRSA-MW2 was grown overnight at 37 °C in TSB under aerobic 77 
conditions and then transferred to anaerobic conditions at 37 °C. Bacteria were added at a final 78 
OD600 of 0.04 to 384-well assay plates (Corning, Corning, NY, USA) containing test compounds 79 
at a final concentration of 2.86 µg/mL. Adult sterile worms (15 were then added to each well using 80 
a Complex Object Parameter Analyzer and Sorter (COPAS, Union Biometrica, Holliston, MA, 81 
USA). After 5-days of incubation at 25 °C, the plates were washed (to remove bacteria) with a 82 
microplate washer and Sytox Orange (Life Technologies, Carlsbad, CA, USA) was added to 83 
selectively stain dead worms. After overnight incubation at 25 °C, the wells were imaged using an 84 
Image Xpress Micro automated microscope (Molecular Devices, Sunnyvale, CA, USA), capturing 85 
both transmitted light and TRITC (535 nm excitation, 610 nm emission) fluorescent images with 86 
a 2X objective. Images were processed using the open source image analysis software CellProfiler 87 
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(http://www.cellprofiler.org/). The ratio of Sytox worm area to bright field worm area and the 88 
resultant percentage survival data were calculated by the software for each well 9. Assays were 89 
completed in duplicate. 90 
Hit compounds. The compounds were an N-hydroxy indole (NHI) 1, a melamine derivative 2, 91 
indole isothiocyanate (ITC) 3 and a protonophore 4 related to carbonyl cyanide m-chlorophenyl 92 
hydrazone (CCCP). Compounds 1 (6-hydroxy-7,8,9,10-tetrahydro-[1,2,5]oxadiazolo[3,4-93 
c]carbazole) and 2 (2-N,4-N-ditert-butyl-6-hydrazinyl-1,3,5-triazine-2,4-diamine) were purchased 94 
from Asinex (Winston-Salem, NC, USA). Compound 3 (1-(2-isothiocyanatoethyl)-1H-indole) 95 
was purchased from Lifechemicals (Burlington, Canada) and compound 4 (3, 2-[[4-96 
(difluoromethylsulfanyl)phenyl] hydrazinylidene]propanedinitrile) was purchased from Enamine 97 
(Monmouth, NJ, USA). All compounds were dissolved in DMSO (Sigma-Aldrich, St. Louis, MO, 98 
USA) to obtain 10 mg/mL stock solutions that were diluted for experiments.  99 
Antibacterial susceptibility assays. In vitro antibacterial activities were tested using the broth 100 
microdilution method 12. Assays were carried out in triplicate using Müller-Hinton broth (BD 101 
Biosciences, Franklin Lakes, NJ, USA) in 96-well plates (BD Biosciences) with a total assay 102 
volume of 100 µL. Two-fold serial dilutions were prepared over the concentration range 0.01−64 103 
µg/mL. An initial bacterial inoculum was adjusted to OD600 = 0.06 and incubated with test 104 
compounds at 35 °C for 18 hours. OD600 was measured and the lowest concentration of compound 105 
that suppressed bacterial growth was reported as its MIC13. Broth cultures (10 µL) from the MIC 106 
assays were plated onto Müller-Hinton agar (BD Biosciences) and after overnight incubation at 37 107 
°C the lowest concentration at which colonies were not observed was reported as the minimal 108 
bactericidal concentration (MBC). 109 
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Time to kill assays. The antibacterial properties of 1-4 against MRSA-MW2 were further 110 
examined using time to kill assays, as previously described 14. Briefly, overnight cultures of S. 111 
aureus MW2 were diluted in fresh TSB to a density of 108 cells/mL and placed into 10 mL tubes 112 
(BD Biosciences). Test compounds at 4x MIC were added and the tubes incubated at 37 °C, with 113 
agitation. Aliquots were periodically drawn from the tubes over a 4 h period, serially diluted with 114 
TSB and plated onto tryptic soy agar (TSA; BD Biosciences). CFUs were then enumerated after 115 
overnight incubation at 37 °C. Assays were carried out in triplicate. 116 
Membrane permeabilization assays. Sytox Green (Life Technologies, Carlsbad, CA, USA) was 117 
used to probe the effects of 1-4 on MRSA-MW2 membrane permeabilization, as previously 118 
described 15. Assays were carried out in duplicate in 96 wells plates (Corning). Bacterial cells were 119 
harvested from logarithmically growing cultures by centrifugation at 3724 g for 5 minutes, washed 120 
twice with phosphate buffered saline (PBS, pH 7.4) and resuspended in PBS to OD595 nm = 0.2. 121 
Sytox Green was added at a final concentration of 5 µM and cells were incubated in the dark for 122 
30 min. Cell suspensions (50 µL) were added to 50 µL of compound (64 µg/mL in PBS), and the 123 
fluorescence intensity was measured (excitation 485 nm, emission 530 nm) periodically over 60 124 
minutes. DMSO was included as the vehicle control. Membrane effects of compounds were 125 
indicated by an increase in cellular fluorescence caused by enhanced permeability of the DNA 126 
staining, membrane impermeable dye.  127 
Intracellular MRSA killing assays. RAW 264.7 macrophages were used to examine intracellular 128 
killing of MRSA-MW2 by 1-4, as described by Schmitt et al 16. Macrophages were grown in 129 
Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Grand Island, NY, USA) supplemented 130 
with 10% fetal bovine serum (FBS) (Gibco) and 1% penicillin/streptomycin (Gibco) and 131 
maintained at 37 °C in 5% CO2 17,18. Cells (50,000) in antibiotic and serum free DMEM were 132 
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seeded in 12-well plates 24 h prior to infection. MRSA-MW2 (multiplicity of infection (MOI) = 133 
50) were added to macrophages and phagocytosis allowed to proceed. Planktonic bacteria were 134 
removed after 2 h and DMEM supplemented with 200 µg/mL gentamicin was added for 2 h to 135 
eliminate extracellular bacteria. Antibiotic and serum-free DMEM with and without test 136 
compounds was added and the cells incubated in a 5% CO2. After 4, 8, 12, or 24 h SDS was added 137 
to a final concentration of 0.02 % to lyse the macrophages only (i.e. not ingested bacteria). Cell 138 
lysates were diluted serially with TSB, plated onto TSA plates and CFUs enumerated. Vancomycin 139 
(8 µg/mL) was used as a positive control and DMSO 0.1% as the negative control. Assays were 140 
carried out in triplicate 19. 141 
Human blood cell (RBC) hemolysis assays. Human erythrocytes (Rockland Immunochemicals, 142 
Limerick, PA, USA) were used to measure the hemolytic activity of the compounds, as described 143 
by Isnansetyo et al 20. Briefly, human erythrocytes (4%, in PBS, 50 µL) were added to 50 µL of 144 
serially diluted test compounds in PBS in 96-well plates. After incubating at 37 °C for 1 h, the 145 
plates were centrifuged at 500 x g for 5 min and 50 µL of the supernatant from each well was 146 
transferred to a second 96-well plate. Absorbance (540 nm) was used as a measure of hemolytic 147 
activity. Assays were carried out in triplicate. 148 
Cytotoxicity assay. Mammalian cell lines HepG2 (hepatic cell line), MKN-28 (gastric cell line), 149 
HKC-8 (renal cell line) were used to determine the cytotoxicity of the compound, as detailed 150 
elsewhere 17,21,22. Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, 151 
Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco) and 1% 152 
penicillin/streptomycin (Gibco) and maintained at 37°C in 5% CO2. Cells were harvested and 153 
suspended in DMEM, and 100 µl of cells were added to each well at a final concentration of 5 x 154 
104 cells. The compound was serially diluted in serum and antibiotic-free DMEM and added to the 155 
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monolayer and incubated at 37°C in 5% CO2 for 24 h. For the last 4 h of this 24 h incubation 156 
period, 10 µl of 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2, 4-disulfophenyl)-2H-tetrazolium (WST-157 
1) solution (Roche, Mannheim, Germany) was added to each well. The WST-1 reduction was 158 
measured at 450 nm using Vmax microplate reader (Molecular Device Sunnyvale, CA, USA). This 159 
assay was done in triplicate, and the percentage of survival was calculated by comparing with 160 
DMSO-treated vehicle control. 161 
Checkerboard assays. Antibacterial synergy for combinations of compounds 1-4 with each other 162 
and clinical antibiotics from various class of antibacterial agents such as fluoroquinolone, 163 
tetracycline, aminoglycosides, macrolides and glycopeptides (ciprofloxacin, doxycycline, 164 
erythromycin, gentamicin, streptomycin and vancomycin) was tested for using checker board 165 
assays. Cultures of MRSA-MW2 were adjusted to OD600 = 0.06 and added to compound pairs that 166 
had been serially diluted in the same 96 well plates, vertically for one compound and horizontally 167 
for the other. Assays were carried out in triplicate as described for antibacterial susceptibility 168 
assays.  The combinatorial inhibitory concentration was indicated by fractional inhibitory 169 
concentration index (FICI) was calculated using the formula: MICA combination / MICA alone + 170 
MICB combination / MICB alone 23.   171 
Statistical analysis. Statistical analysis (Two-way ANOVA followed by Bonfererroni post-test) 172 
was carried out using GraphPad Prism version 6.04 (GraphPad Software, La Jolla CA, USA) and 173 
p values of <0.05 were considered significant. 174 
  175 
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Results  176 
HTS assay. We previously reported a C. elegans HTS assay for the identification of novel 177 
antibacterial hits against MRSA 9 and screened 3,930 compounds in Asinex 1 library and 3,892 178 
compounds in Life chemicals library 9,15. During the screening, we identified that compounds 1-4 179 
(Figure 1) prolonged the survival of C. elegans infected with MRSA-MW2 at a concentration of 180 
2.86 µg/mL compared to the DMSO control (Figure 2 A-D).  181 
Antibacterial susceptibility. The antibacterial activity of the four hits was evaluated against a 182 
panel of ESKAPE pathogens. All four compounds were found to inhibit the growth of the Gram-183 
positives MRSA-MW2 and E. faecium (MICs 2-8 mg/mL, Table 1). Compounds 1 and 4 were 184 
slightly active against A. baumannii (MIC = 32 µg/mL) but no other activity was observed against 185 
Gram-negatives. The MIC of vancomycin was 4 µg/mL against Gram-positives and polymyxin B 186 
was 2-8 µg/mL against Gram-negatives in the ESKAPE panel (Table 1). The minimum 187 
bactericidal concentrations (MBC) of 1 and 4 against MRSA-MW2 were 64 and 32 µg/mL, 188 
respectively, while the MBC of compounds 2 and 3 was > 64 µg/mL. The MIC of oxacillin, 189 
vancomycin, polymyxin B, was tested with various clinical S. aureus strains. All the clinical strains 190 
were resistant to oxacillin. The MICs of compounds 1-4 were listed in Table 2. Time to kill assays 191 
were used to further confirm the bactericidal/bacteriostatic properties of 1-4 against MRSA-MW2. 192 
When cells were exposed to the compounds at 4X MIC all showed only bacteriostatic activity 193 
relative to DMSO controls (Figure 3). While compounds 1, 2 and 4 inhibited bacterial growth, 194 
ITC derivative 3 was able to reduce CFU/mL counts by 2-log10.  195 
Membrane permeabilization. To evaluate the membrane effects of 1-4, uptake of the membrane-196 
impermeable DNA-binding fluorescent dye Sytox Green into MRSA-MW2 cells was monitored 197 
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in the presence/absence of the compounds. Exposure of cells to the compounds at 64 μg/mL 198 
identified that only 2 and 3 show effects on MRSA membranes, as indicated by increases in cellular 199 
fluorescence (Figure 4). Observing membrane effects with 2 and 3 was in agreement with previous 200 
reports on members from the melamine 24 and ITC classes 25. In contrast, compounds 1 and 4 201 
showed no changes in cellular fluorescence (Figure 4), indicating that they do not elicit their 202 
antibacterial effects through action on membranes. 203 
Killing of intracellular MRSA in macrophages.  It is known that S. aureus can act as an 204 
intracellular pathogen 26. To explore the effects of 1-4 on intracellular MRSA, RAW 264.7 205 
macrophages were exposed to MRSA-MW2 cells and treated with test compounds at 1x MIC, 206 
vancomycin (positive control, 8 µg/mL, 2x MIC) and 0.1 % DMSO (negative control). 207 
Compounds 1, 2 and 4 were found to significantly inhibit the growth of intracellular MRSA 208 
relative to DMSO (p<0.001). While vancomycin was able to produce a slight reduction in bacterial 209 
counts, compound 3 completely cleared intracellular MRSA after 8 hours of treatment (Figure 210 
5A). The difference observed between the time to kill kinetics and intracellular killing of MRSA 211 
when treated with compound 3, may due to limited duration (only 4 hours) of compound exposure 212 
to bacterial cells in time to kill kinetics. However, we treated MRSA-MW2 cells with compounds 213 
1-4, and incubated as indicated in the macrophage assay and we observed that compound 3 killed 214 
the planktonic bacteria after prolonged incubation (Figure 5B).   215 
Human red blood cell lysis assays and cytotoxicity. Serial dilutions of 1-4 were added to human 216 
red blood cells to establish whether they show hemolytic activity. It was found that none of the 217 
compounds showed hemolysis at concentrations up to 64 µg/mL. Serially diluted triton-X (0.001 218 
to 1%) as a positive control were added to human RBCs caused substantial lysis (Figure 6A). 219 
Hepatotoxicity of the test compounds 1-4 was evaluated using the liver cell line HepG2, commonly 220 
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used to test the toxicity of compounds 14. In this series of experiments, the IC50 of the compound 221 
1-4 against HepG2 was 32, 16, 8, and 1 µg/mL respectively (Figure 6B). Also, we tested the 222 
cytotoxicity with gastric and renal cell lines and we observed similar results with hepatic cell lines. 223 
The IC50 of compounds 1-4 was against MKN-28 was 64, 32, 4 and 4 µg/mL respectively (Figure 224 
6C); and against HKC-8 was 64, 32, 2, 2 µg/mL respectively (Figure 6D). The IC50 of compounds 225 
3 and 4 were high in mammalian cell lines, however, we are working on the analogues to eliminate 226 
the cytotoxicity as well as sustain potent antimicrobial ability. In addition, we monitored the 227 
survival of macrophages in the presence of test compounds 1-4 at MIC level and observed that the 228 
compound 3 was harmful to macrophages (Figure 6E) and bacteria (Figure 5B).    229 
Antibacterial synergy. Use of paired combinations of drugs can reduce bacterial resistance and 230 
even restore clinical efficacy of some antibiotics 27. Checkerboard assays were performed to 231 
establish whether compounds 1-4 act synergistically against MRSA-MW2 when paired with one 232 
another and five clinical antibiotics from different class of antibacterials (i.e. ciprofloxacin, 233 
doxycycline, erythromycin, gentamicin, streptomycin and vancomycin). Paired combinations of 234 
compounds and their observed fractional inhibitory concentration indices (FICI) are listed in Table 235 
3. Synergistic effects, where the combined antibacterial activity of the two agents is more than the 236 
sum of their effects alone, were identified by FICI ≤ 0.5, antagonism by FICI > 4.0 and ‘no 237 
interaction’ by FICI > 0.5 -  4.0 28.  238 
Antagonism was not observed for any of the compound combinations. Compounds 1-4 239 
showed no interactions when paired with one another but all four compounds showed synergy with 240 
at least one antibiotic. Ciprofloxacin was synergistic with compounds 1, 2 and 4, with compound 241 
4 also showing synergy with doxycycline. Compound 3 showed no synergy with ciprofloxacin or 242 
doxycycline but synergized with all four of the antibiotics. Previous studies have reported that the 243 
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activity of natural ITCs is enhanced by clinical antibiotics 29-31, in agreement with our observations 244 
with 3. 245 
246 
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Discussion 247 
Bacterial resistance to antibiotics has become a major global public health threat, with drug-248 
resistant bacteria causing significant and increasing mortality and morbidity 32. There is an urgent 249 
need to develop new antibiotics, ideally with novel mechanisms of action to slow the onset of 250 
resistance. Lead antibacterials are usually either synthesized chemically or isolated from natural 251 
products that exhibits antibacterial activity 33,34. We completed a C. elegans-MRSA HTS study 252 
and identified four small molecules that rescued nematodes from MRSA infection at 2.86 µg/mL 253 
9.  254 
Compound 1 represents a [1,2,5]oxadiazolo derivative from the NHI class, which are 255 
known to have antibacterial activity against Gram-positive organisms 35. Natural products bearing 256 
the NHI group, such as the nocathiacins and thiazomycins and their semi-synthetic analogues, 257 
exhibit activity against Gram-positive bacteria by inhibiting protein synthesis through direct 258 
interactions with the bacterial 50s ribosome 35. The related 7-hydroxy indole reportedly shows 259 
anti-virulence effects against P. aeruginosa 36. 260 
Compound 2 was a derivative from the widely-studied melamine class, whose examples 261 
have found use in antimicrobial polymers 37 and as water and food disinfectants 38. Melamine 262 
derivatives related to compound 2 have found applications in biocidal polymers, in food industries, 263 
as water disinfectants and as additives in livestock feeds 37,39. Reports have described the 264 
antibacterial activity of melamine 40 and Weaver AJ Jr, et al. reported that melamine derivatives 265 
target the bacterial membrane via non-specific interactions 24.  266 
Compound 3 contained an alkyl ITC attached to an indole nitrogen via a 2-carbon linker. 267 
ITC derivatives are known to show activity against Gram-positive and Gram-negative bacteria 41. 268 
ITCs are also present in several plant natural products 42 and can produce both bactericidal and 269 
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bacteriostatic activities against a range of bacterial pathogens 43. ITCs are known to react with 270 
amines and alcohols due to their highly electrophilic character 44, suggesting non-target specific 271 
mechanisms for compound 3. However, Breier et al., reported that ITCs can selectively inhibit the 272 
ATP binding sites of P-ATPase in bacteria via  reaction with a cysteine residue, suggesting the 273 
possibility of target-specific activity 45. Also, Sofrata et al., reported that benzyl isothiocyanate 274 
promotes outer membrane penetration in Gram-negative bacteria, leading to effects similar to those 275 
observed with cationic antimicrobial peptides 46. 276 
Compound 4 was a diarylacylhydrazone and close structural analog of the protonophore 277 
CCCP. Protonophores are molecules that dissipate the proton motive force in bacterial membranes 278 
leading to growth inhibition [27]. Compounds of this type were recently shown to exert non-279 
specific (protonophoric) antibacterial effects against the Gram-positive bacterium Clostridium 280 
difficle 47. Clinically used protonophores include the salicylanilide anthelmintics niclosamide, 281 
oxyclozanide and closantel, which are also known to show anti-staphylococcal activity 9,14. 282 
Characterization of the antibacterial properties of 1-4 here confirmed that they each show 283 
direct activity against two Gram-positives, inhibit intracellular growth of MRSA in macrophages, 284 
are non-hemolytic and synergize with clinical antibiotics. Future work focusing on the specific 285 
characteristics of each compound would likely provide further insights into their mechanisms of 286 
action. For example, studies exploring the effects of compound 1 on bacterial 50s ribosomes and 287 
its anti-virulence activity against S. aureus would be informative. Indole ITC 3 showed the most 288 
interesting activity of the four compounds, being able to clear intracellular MRSA from 289 
macrophages and synergizing with multiple antibiotics against MRSA, possibly due to its 290 
membrane permeabilizing properties (Figure 4). While it is unlikely that 3 could be developed into 291 
a drug for systemic MRSA infections due to the reactive ITC group, it would be interesting to 292 
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study its activity against skin and other body-surface MRSA infections in mammalian models, 293 
particularly in combination with the antibiotics it was shown here to synergize with.   294 
In conclusion, screening for novel antibacterial compounds using a whole-animal HTS 295 
identified novel small molecule hits with anti-staphylococcal activity. Combinatorial activity with 296 
clinical antibiotics might decrease the chances of emerging antimicrobial resistance and absence 297 
of antagonism with other compounds can be a valid credential of the hit compounds. Validation 298 
of the activity of the compounds here suggest further investigations and warrant further evaluation 299 
in mammalian models. 300 
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Figure Legends 445 
Figure 1. Chemical structures of compounds 1-4.  446 
Figure 2. Images from C. elegans-MRSA HTS. Worms observed in light microscope (left) are 447 
outlined in red and dead worms were identified in Sytox Orange-stained images (right) and were 448 
marked in green. Compounds were classified as hits based on extension of survival of MRSA-449 
MW2 infected worms. A compound 1; B compound 2; C compound 3; D compound 4; E 450 
Vancomycin; F DMSO. 451 
Figure 3. Time to kill assay. MRSA-MW2 cells were exposed to compounds 1-4 at 4X MIC and 452 
cell viability was monitored over 4 h. Data represent the mean ± SEM (n = 3). 453 
Figure 4. Bacterial membrane permeabilization assay. Cellular fluorescence of MRSA-MW2 454 
cells treated with Sytox Green and compounds 1-4 (64 µg/mL) was monitored over a 1 h period.  455 
Figure 5. A. Killing of intracellular MRSA-MW2 in macrophages. MRSA-MW2 cells were 456 
exposed to RAW 264.7 macrophages, treated with test compounds 1-4 at 1X MIC and the killing 457 
of internalized bacteria was measured by CFU enumeration. Vancomycin (8 µg/mL) was used as 458 
a positive control and DMSO 0.1% as the negative control. Data represent the mean ± SEM (n = 459 
3). ***p<0.001, two-way ANOVA with Bonfererroni post-test comparing DMSO control at 24 460 
hour time point. B. Killing of planktonic MRSA-MW2. MRSA-MW2 cells were exposed test 461 
compounds 1-4 at 1X MIC and the CFU was measured. 462 
Figure 6. Cytotoxicity of compounds 1-4. A. Hemolytic activity. Human RBCs were exposed 463 
to 2-fold serial dilutions of compounds and hemolysis was measured after 1 hour. Serially diluted 464 
triton-X (0.001 to 1%) was included as a positive control. B-D. Cytotoxicity. Mammalian cells 465 
(HepG2, MKN-28, HKC-8) were treated with 2-fold serial dilutions of compounds and the 466 
24 Tharmalingam et al., 
 
cytotoxicity was measured after 24 h by WST-1. B. HepG2 cells; C. MKN-28; D. HKC-8. Data 467 
represent the mean ± SEM (n = 3).   468 
Figure 1. Chemical structures of compounds 1-4.  1 
  2 
Figure 2. Images from C. elegans-MRSA HTS.  3 
   4 
  5 
   6 
Figure 3. Time to kill assay.  7 
   8 
Figure 4. Bacterial membrane permeabilization assay.  9 
  10 
Figure 5. Killing of intracellular MRSA-MW2 in macrophages. 11 
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Table 1. Antibacterial activity (µg/mL) of compounds 1-4 against ESKAPE pathogens. 
  
 1 2 3 4 Vancomycin Polymyxin B 
 MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
Staphylococcus 




8 ND 8 >64 8 >64 2 >64 4.0 64 >64 >64 
Acinetobacter 




>64 >64 >64 >64 >64 >64 >64 >64 >64 >64 8 8 
Klebsiella 




>64 >64 >64 >64 >64 >64 >64 >64 >64 >64 2 4 
Table 2. Antibacterial activity (µg/mL) of compounds 1-4 against clinical S. aureus 
pathogens. 
  
 MIC (µg/mL)  
   
 1 2 3 4 Vancomycin PolymyxinB Oxacillin 
S. aureus BF1 4 8 8 2 2 >64 >64 
S. aureus BF2 4 8 8 2 2 >64 >64 
S. aureus BF3 4 8 8 2 2 >64 32 
S. aureus BF4 4 8 8 2 2 >64 16 
S. aureus BF5 4 8 8 2 2 >64 >64 
Table 3. Fractional inhibitory concentration index (FICI) of compounds 1-4 used in paired 





Compound Clinical antibiotics 
1 2 3 4 CIP DOX EMN GMN STN VAN 
1  0.75 1.0 0.75 0.5 1.0 0.75 0.75 2.0 2.0 
2 0.75  1.0 0.75 0.5 1.0 1.0 1.0 0.625 1.0 
3 1.0 1.0  1.0 1.0 0.75 0.5 0.5 0.5 0.5 
4 0.75 0.75 1.0  0.5 0.5 0.75 1.0 1.0 1.0 
 
CIP- Ciprofloxacin; DOX- Doxycycline; EMN- Erythromycin; GMN-Gentamicin; STN- Streptomycin; 
Van- Vancomycin.  
Synergy FICI ≤ 0.5, antagonism FICI > 4.0, no interaction 0.5 > FICI ≤ 4.0 28. 
 
